Medpace MEDP
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Medpace (MEDP) Core Market Data and Business Metrics
Latest Closing Price
$311.23Price-Earnings Ratio
24.64Total Outstanding Shares
30.47 Million SharesDividend
No dividendSIC Description
Services-commercial Physical & Biological ResearchPrimary Exchange
NASDAQHeadquarters
5375 Medpace Way, Cincinnati, OH, 45227
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 399,282 Shares | 3.11 | 3/14/2025 | 1,242,942 Shares |
| 375,950 Shares | 3.89 | 2/28/2025 | 1,463,684 Shares |
| 381,887 Shares | 3.27 | 2/14/2025 | 1,247,802 Shares |
| 186,994 Shares | 5.97 | 1/31/2025 | 1,115,679 Shares |
| 237,650 Shares | 4.23 | 1/15/2025 | 1,004,376 Shares |
| 249,842 Shares | 4.62 | 12/31/2024 | 1,154,352 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $423.99 Million |
| Net Cash Flow From Investing Activities | $-28.31 Million |
| Net Cash Flow From Operating Activities | $608.82 Million |
| Net Cash Flow From Financing Activities | $-154.01 Million |
| Net Cash Flow From Financing Activities, Continuing | $-154.01 Million |
| Net Cash Flow From Operating Activities, Continuing | $608.82 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss | $404.39 Million |
| Net Income/Loss Attributable To Parent | $404.39 Million |
| Revenues | $2.11 Billion |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Operating Expenses | $29.25 Million |
| Basic Earnings Per Share | $13.06 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $399.71 Million |
| Other Comprehensive Income/Loss | $399.71 Million |
| Comprehensive Income/Loss | $399.71 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Wages | $84.93 Million |
| Other Current Liabilities | $987.10 Million |
| Liabilities | $1.28 Billion |
| Assets | $2.10 Billion |
| Equity Attributable To Parent | $825.54 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||